Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Quality of Life After Permanent Interstitial Iodine Seed Prostate Brachytherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02652000
Recruitment Status : Completed
First Posted : January 11, 2016
Last Update Posted : December 13, 2016
Sponsor:
Collaborator:
University of Zurich
Information provided by (Responsible Party):
Daniel Rudolf Zwahlen, Kantonsspital Graubuenden

Brief Summary:
Retrospective study to analyze Quality of life in men after iodine seed brachytherapy for localized prostate cancer

Condition or disease Intervention/treatment
Neoplasms, Prostate Other: No intervention in this retrospective study

Detailed Description:
Retrospective Evaluation of Quality of life data collected on men who underwent iodine seed brachytherapy at the University Hospital Zurich

Layout table for study information
Study Type : Observational
Actual Enrollment : 50 participants
Time Perspective: Retrospective
Official Title: Retrospective Analysis of Quality of Life After Permanent Interstitial Iodine Seed Brachytherapy for Prostate Cancer
Study Start Date : October 2009
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine



Intervention Details:
  • Other: No intervention in this retrospective study
    No Intervention in this retrospective Analysis.


Primary Outcome Measures :
  1. CTCAE v4.03ff Grade 1-4 Sexual/Reproductive Function [ Time Frame: 5 years (2009-2014) ]
    Scale


Secondary Outcome Measures :
  1. CTCAE v4.03ff Grade 1-4 Gastrointestinal [ Time Frame: 5 years (2009-2014) ]
    Scale

  2. CTCAE v4.03ff Grade 1-4 Renal/Genitourinary [ Time Frame: 5 years (2009-2014) ]
    Scale

  3. International Prostate Symptom Score (IPSS) [ Time Frame: 5 years (2009-2014) ]
    Scale

  4. International Index of erectile function, five items (IIEF-5) [ Time Frame: 5 years (2009-2014) ]
    Scale



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   48 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients having had idodine seed brachytherapy for localized prostate cancer between 2009 and 2014
Criteria

Inclusion Criteria:

  • Male > 18 years of age
  • iodine seed brachytherapy for localized prostate cancer at the University Hospital Zurich

Exclusion Criteria:

  • No iodine seed brachytherapy for localized prostate cancer at the University Hospital Zurich

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02652000


Locations
Layout table for location information
Switzerland
Kantonsspital Graubuenden, Department of Radiaton Oncology
Chur, Switzerland, 7000
Sponsors and Collaborators
Kantonsspital Graubuenden
University of Zurich
Investigators
Layout table for investigator information
Principal Investigator: Daniel R Zwahlen, MD, MBA Kantonsspital Graubuenden
Layout table for additonal information
Responsible Party: Daniel Rudolf Zwahlen, MD, MBA, Kantonsspital Graubuenden
ClinicalTrials.gov Identifier: NCT02652000    
Other Study ID Numbers: KEK-ZH-Nr. 2015-0573
First Posted: January 11, 2016    Key Record Dates
Last Update Posted: December 13, 2016
Last Verified: December 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases